8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance

FACT-JACIE Quality, Traceability, Registry and Regulatory Compliance

Clinical principle: Use the current accreditation edition, law, product label, controlled SOP and assigned reporting pathway. Standards define a quality system and required outcomes; they do not justify invented staffing ratios, universal two-RN checks or fixed audit calendars.

1. FACT-JACIE Scope

The current FACT-JACIE hematopoietic cellular-therapy standards cover clinical programs, marrow and apheresis collection, processing, storage, distribution and administration of hematopoietic progenitor, immune-effector and genetically modified cellular products. Accreditation scope identifies adult/pediatric, autologous/allogeneic, product and facility activities. A program may use partner facilities under written agreements, but responsibilities for traceability, eligibility records, storage, transport, release and adverse events must be explicit.

Use the current Ninth Edition and accreditation manual. Requirements change; an older three-year cycle, staffing ratio, room specification or competency list should not be quoted without the applicable standard and scope.

2. Quality Management and CAPA

A written quality management plan identifies leadership, authority, interfaces, critical processes, key performance data and review. Controlled SOPs and records establish version, approval, training, effective date, retention and change control. Critical facilities, equipment, software, suppliers, methods and processes require qualification or validation appropriate to risk.

Report and investigate deviations, near misses, errors, accidents, adverse reactions and complaints under the defined pathway. Root-cause analysis should examine system contributors. Corrective action fixes detected nonconformity; preventive/risk-reduction action addresses recurrence or similar hazards. Assign an owner and due date, implement change/training, and measure effectiveness. Audit and management-review frequency comes from the current standard and quality plan—not automatically quarterly, at 30/60/90 days or every two years for every document.

3. Chain of Identity and Custody

Chain of identity (COI) maintains the association among donor or autologous patient, collected material, manufactured/processed product and intended recipient. Chain of custody (COC) records who controlled the product, where and when, its storage/transport conditions, and each handoff/disposition. Standard HCT products use required coding such as ISBT 128 or Eurocode; commercial products may also use manufacturer-specific identifiers and portals.

Before thaw or administration, follow the controlled SOP and label: match required patient identifiers, product/donation/manufacturer identifiers, product type, intended recipient, order, release/status records, dose/volume, expiration, bag integrity, storage/transport condition and required compatibility/manipulation. Verify consent, premedications and emergency resources. Verifier number and professional roles are product/SOP-specific; a second checker is common but “exactly two RNs” is not a universal FACT rule. Quarantine discrepancies and escalate—never relabel or resolve identity at bedside without authority.

4. CIBMTR and SCTOD

The U.S. Stem Cell Therapeutic and Research Act requires reporting to the Stem Cell Therapeutic Outcomes Database for qualifying allogeneic HCT when the transplant, collection or cord source meets U.S. criteria. Autologous HCT is not part of the federal SCTOD mandate. CIBMTR manages SCTOD and also receives autologous HCT and cellular-therapy data through participation, accreditation, research, payer, product/manufacturer and other agreements.

Common data include pre-treatment recipient/disease/donor/product details, conditioning, engraftment, toxicity, response, GVHD, relapse, subsequent malignancy and survival at early and longitudinal time points. Follow the currently assigned FormsNet pathway and deadlines rather than memorizing obsolete form numbers. Accurate source documentation, timely correction and privacy protections are nursing and program responsibilities.

5. FDA and Product Controls

21 CFR Part 1271 establishes HCT/P registration, donor-eligibility, current good tissue practice and related requirements, with applicability and exceptions determined by product and use. Products that do not meet the criteria for regulation solely under PHS Act section 361 may require IND/BLA regulation under section 351 and the food/drug laws. Standard marrow, peripheral-blood, cord, manipulated, combination and gene-modified products do not all fit one simplified table; use regulatory/quality review and the product's authorized status.

For covered allogeneic donation, use current donor-history screening, examination, communicable-disease testing, timing, eligibility determination, quarantine/release and exception documentation. Do not use a memorized pathogen list as the SOP.

On June 27, 2025 FDA eliminated REMS for the six then-approved CD19- and BCMA-directed autologous CAR T products. This removed REMS site certification and training/access requirements; Aucatzyl had not carried that REMS. Current labels still contain boxed warnings, monitoring, proximity/driving, pre-infusion resource and adverse-event instructions, which must be checked product by product. FDA also retained adverse-event reporting and manufacturer postmarketing studies with 15-year follow-up for long-term safety/subsequent malignancy risk.

6. Nursing Application

At a handoff or product discrepancy, preserve the product and records in their controlled state, stop the affected step when safety is uncertain, notify the authorized clinical/processing/quality contacts, and document facts without backdating or speculative correction. The quality system determines quarantine, investigation, release or disposition. This protects both the patient and the traceable vein-to-vein record.

7. Who Audits What: FACT, The Joint Commission, FDA and REMS

The outline names FACT, The Joint Commission, and REMS together under accreditation, and candidates lose items by treating them as one oversight system. They are separate bodies with distinct authority.

FACT (with JACIE internationally) is voluntary, specialty-specific accreditation for cellular therapy programs. It sets standards for the clinical program, the collection facility, and the processing laboratory, and it is what payers and manufacturers most often require before a program may deliver certain products. Its inspections examine cellular therapy practice in detail.

The Joint Commission accredits the hospital as a whole against organization-wide standards - National Patient Safety Goals, medication management, infection prevention, environment of care - and is not cellular-therapy-specific. A program can satisfy one and fail the other.

The FDA regulates the products themselves, through the licensure of manufactured cellular products, requirements for minimally manipulated tissue, adverse event reporting, and the recall and deviation pathways.

A REMS is a product-specific FDA-mandated safety program, not an accreditation. It may require prescriber or site certification, documentation, or patient materials, and REMS requirements change as the FDA reassesses individual products. The correct nursing posture is to verify whether a REMS currently applies to the specific product being given rather than to assume a class-wide answer.